Ann: BFS Update and Target Production Capacity Increase, page-43

The problem is the years of inactivity waiting for the SML. Now management pushing timelines out further.
This is a honey pot for short term traders (which tend to drive prices), to push the price lower, after consolidation.
Have a look at ARX (health sector) but generating real revenues and not attracting attention from the market. Well undervalued compared to peers. Listed, pumped after the IPO, then the IPO traders sold and been undervalued, for many months (Covid did affect performance last year, but sales have recovered well).
Think we can expect a similar result if PEK consolidates - if they don't have a solid timeline laid out, before they consolidate.

Not investment advice. DYOR